{
  "id": 7225053,
  "title": "Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer",
  "url": "https://urgent.news/2026/09/14/update-shows-sustained-overall-survival-benefit-with-adjuvant",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T01:50:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-sustained-survival-benefit-adjuvant-osimertinib.html"
  },
  "original_language": "en",
  "account": "An 8-year update from the Phase III ADAURA trial revealed that adjuvant osimertinib continues to offer an 8-year overall survival advantage for resected EGFR-mutated non-small cell lung cancer (NSCLC) patients. In the study, 682 patients with completely resected EGFR-mutated stage IB–IIIA NSCLC were randomly assigned to receive osimertinib 80 mg daily or placebo for up to 3 years. The results, published in the Journal of Thoracic Oncology, showed that patients on osimertinib had a 79% overall survival rate compared to 64% in the placebo group, a 15-percentage-point difference. The hazard ratio for overall survival was 0.52 (95% CI, 0.39–0.71), indicating a 52% reduction in the risk of death with osimertinib. The survival benefit was observed across predefined subgroups and persisted even when considering adjuvant chemotherapy.",
  "summary": "An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}